Haemonetics (HAE) in Focus: Stock Adds 6.8% in Session – Tale of the Tape

This developer of automated blood component collection devices and surgical blood salvage devices has seen one negative estimate revision in the last 30 days. However, the Zacks Consensus Estimate has remained unchanged over the same period. Yesterday’s price climb is encouraging though, so make sure to keep a close watch on this firm in the near future.

Haemonetics currently holds a Zacks Rank #4 (Sell).

A better-ranked Med-Products stock is ICU Medical, Inc. (ICUI) with a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>